Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Pediatr Blood Cancer. 2007 Mar;48(3):285–291. doi: 10.1002/pbc.20815

Fig. 2.

Fig. 2

Overall survival (OS) for POG 9530 eligible patients. Three-year OS was 79± 11% for high-risk or nongerminomatous patients. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]